LONDON (Reuters) - Shire's Gaucher disease drug Vpriv significantly improved lumbar spine bone density, while Sanofi's Cerezyme did not, according to results from a head-to-head clinical trial presented on Thursday.
used abeka books sonlight homeschool waldorf homeschool
No comments:
Post a Comment